Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES

(GILD)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/15/2019 08/16/2019 08/19/2019 08/20/2019 08/21/2019 Date
62.87(c) 63.14(c) 64.11(c) 63.44(c) 63.94 Last
4 758 927 7 593 275 6 163 388 5 286 556 2 798 566 Volume
-0.40% +0.43% +1.54% -1.05% +0.79% Change
More quotes
Financials (USD)
Sales 2019 22 314 M
EBIT 2019 11 591 M
Net income 2019 4 273 M
Debt 2019 3 023 M
Yield 2019 3,97%
Sales 2020 22 545 M
EBIT 2020 11 225 M
Net income 2020 7 101 M
Debt 2020 712 M
Yield 2020 4,32%
P/E ratio 2019 18,1x
P/E ratio 2020 11,1x
EV / Sales2019 3,74x
EV / Sales2020 3,60x
Capitalization 80 344 M
More Financials
Company
Gilead Sciences specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98%): for the treatment of HIV, hepatitis B virus and hepatitis C virus (98.5% of net sales) and other (1.5%; primarily... 
More about the company
Surperformance© ratings of Gilead Sciences
Trading Rating : Investor Rating :
More Ratings
Latest news on GILEAD SCIENCES
08/19Who is next in big pharma's merger spree?
RE
08/16GILEAD SCIENCES : European Medicines Agency Validates Marketing Application for ..
AQ
08/15European Medicines Agency Reviews Arthritis Treatment by Gilead, Galapagos
DJ
08/15STEALTH BIOTHERAPEUTICS : Reports First Half 2019 Financial Results and Recent B..
AQ
08/15GILEAD SCIENCES : Québec Provides Access to Biktarvy® for the Treatment of HIV
AQ
08/13GILEAD SCIENCES : Report
CO
08/12GILEAD SCIENCES : China National Medical Products Administration Approves Biktar..
AQ
08/12GILEAD SCIENCES : China National Medical Products Administration Approves Biktar..
AQ
08/09MARKET SNAPSHOT: Dow Ends Friday Trade Lower But Indexes Chipped Away At Ugly..
DJ
08/09GILEAD SCIENCES : China National Medical Products Administration Approves Biktar..
BU
More news
Analyst Recommendations on GILEAD SCIENCES
More recommendations
Sector news : Bio Therapeutic Drugs
08/15European Medicines Agency Reviews Arthritis Treatment by Gilead, Galapagos
DJ
08/12REGENERON PHARMACEUTICALS : Two Experimental Ebola Drugs Reduce Mortality Rate
DJ
08/08Sarepta says adverse event report for DMD gene therapy erroneously submitted
RE
08/08AGENUS : FDA Accepts AGEN2373 IND, Triggering $7.5 Million Milestone
DJ
08/07Hedge fund Hoplite Capital plans to shut down - letter
RE
More sector news : Bio Therapeutic Drugs
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 80,95  $
Last Close Price 63,44  $
Spread / Highest target 49,7%
Spread / Average Target 27,6%
Spread / Lowest Target -5,42%
EPS Revisions
Managers
NameTitle
Gregg H. Alton Chief Executive & Patient Officer
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
John G. McHutchison Chief Scientific Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES1.42%80 344
VERTEX PHARMACEUTICALS10.87%48 089
REGENERON PHARMACEUTICALS-20.74%32 649
GENMAB26.56%13 270
NEUROCRINE BIOSCIENCES, INC.35.88%9 041
BEIGENE LTD--.--%8 954